Indeed, GCG antagonists, developed as potential glucose-lowering therapies, were associated with an increase in hepatic steatosis [38], suggesting that GCG agonists may reduce hepatic steatosis [39]
Abstract Current management of chronic kidney disease (CKD) in type 1 diabetes centres on glycaemic control, reninangiotensin system inhibition and optimisation of risk factors including blood pressure, lipids and body weight
The team of Eat Fit dietitians works closely with local restaurants, markets and other foodservice establishments to identify and develop dishes that meet the Eat Fit nutritional criteria
Food and Drug Administration (FDA-g)
DO has served as a speaker for Boehringer Ingelheim, Eli Lilly and Novo Nordisk, and served on advisory boards for Roche Diagnostics and Sanofi
doi: 10.1159/000369968 22 SharmaDVermaSVaidyaSKaliaKTiwariV